How concerned should we be for #hydroxychloroquine retinopathy. >4000 pts prospectively followed. 1/2 w RA & 15% w #SLE. New risks Asian with pericentral pattern and overall. Length of time on use and ⬆️wt based dose per day & CKD all risks. Abst#0989 #ACR21 #ACRBest @RheumNow https://t.co/XTfdQpVC7H

In pts w/o RF, liver bx prev suggestd if lifetime cumulative MTX dose was 1-1.5g, then 3.5-4g. All pts in centre offered Fibroscan liver stifness associations: - age, BMI - not cumulative MTX dose maybe survival bias, but what we're doing now is fine! #ACR21 ABST0786 @RheumNow https://t.co/I6IhS3jhmC

Very interesting talks by Dr. Kim and Dr. Hyrich on DMARDs and Cancer risks #ACR21 @RheumNow https://t.co/Dl5WPo7mmj

NORD-STAR Trial: outcomes in tx-naïve, early RA pts after 48w of csDMARDs+GC vs bDMARD (ABAtacept, CerToliZumab, or ToCiluZumab)+MTX ➡️ Superior CDAI remission rates w/ ABA+MTX & CZP+MTX but not TCZ+MTX vs csDMARD+GC ➡️Imaging progression low in all Abst#0825 #ACR21 @RheumNow https://t.co/QaFIF4WNEG

#ACR21 #Abstr0871 📢Argument against HCQ<5mg/kg dose from cardiac perspective in #lupus. A retrospective study N=296 pts, 13% developed CV events.⬇️28% in risk of heart failure, arrhythmia/cardiac death per mg/kg of HCQ in non-smokers @RheumNow #ACRBest https://t.co/6ssd2159R1 https://t.co/tllPWLnFFj

• The Association of Hydroxychloroquine Dosing with Adverse Cardiovascular Events…

B cell repertoire: the new 🔮? An algorithm associating baseline CDAI to BCR sequencing outcomes w/ ✨Isotypes frequency ✨Somatic Hypermutations predicts MTX 12mo response w/ 78% sens & spe #Abstr982 #ACR21 @RheumNow https://t.co/SZaip6xUaO https://t.co/fbWq34gtzc

• B Cells Repertoire Repartition Predicts Response to Methotrexate at 6 and 12 Mo…

PsA impacts many aspects of life. PRO such as VAS pain and HAQ, are commonly assessed. The FACIT-Fatigue scale, ranked the highest by patients. Personalized discussion is vital in assessment and shared decision making @RheumNow #ACR21 Abst#0751 https://t.co/gRfYK4sHc6 https://t.co/f5xjUnXsGQ

• Are Current Patient Reported Outcomes Instruments Optimized to Capture the Enti…

Can patient with low dx activity SLE stop HCQ, or at least try and reduce the dose? Not if you want to avoid flares. If there are safer subgroups to try it in, we haven't found them yet (in fact higher dx activity➡️less risk ?other Rx) SLICC inception #ACR21 ABST0959 @RheumNow https://t.co/NS2V4dEGHv

Do you order EKGs in everyone starting HCQ? Do you avoid HCQ in patients with heart failure? Will these abstracts impact your practice? Click on link to read more....#ACR21 @rheumnow #HCQ https://t.co/fvUZAvNWa8

• Dr. John Cush on Twitter: &quot;Prolonging the Controversy of Hydroxychloroquin…

CARRA STOP-JIA 400pts, Obs study w/ 3 treatments plans : -Step up -Early combination -Biologic first Which one do you think works best? I'd say none: overall 40-60% not achieving CDI off steroids at 24 months. Results: 42% for SU, 52% EC, and 44% BF #Abtr0960 #ACR21 @RheumNow

Don't stop hydroxychloroquine in SLE, even when doing well. Associated with ⬆️flare risk. x2 even when in remission. Abstr#0959 #ACR21 @RheumNow https://t.co/1gGx0V5oxk

CV events go down when #hydroxychloroqine dose goes up in SLE BUT only in non smokers. Maybe due to smoking attention of HCQ levels &/or smoking as a bigger risk for CV over rides HCQ dose? ⬇️cardiac events by 28% in non-smokers abst0871 #ACR21 @RheumNow #RheumPix https://t.co/XxgK7iRXWi

#ACR21 Abst#0836. TCZ switch from IV▶️SC in RA ⭐️11/37 ineffective on SC (30%) ⭐️TCZ IV >8mg/kg, no MTX, h/o ABA failure ass w/ risk of flare on SQ switch 🔥Very relevant w shortages, want more data re: confounders (adherence, disease control) https://t.co/E9pD4SrXqz @Rheumnow

• https://bit.ly/3keDrHK